Primary central nervous system post-transplant lymphoproliferative Disorder in a lung transplant recipient despite reduction of immunosuppression

Q4 Medicine

Transplantation Reports Pub Date : 2025-02-01 DOI:10.1016/j.tpr.2025.100172

K Afshar , JM Kozuch , M Don , C Gaissert , E Golts

引用次数: 0

Abstract

Lymphomas arising in the setting of immune deficiency and/or dysregulation, also known as post-transplant lymphoproliferative disorder (PTLD) is frequently associated with immunosuppressive therapies and the Epstein Barr Virus after solid organ transplantation. Primary central nervous system PTLD (PCNS-PTLD) is extremely rare. Our group presents only the third reported case of PCNS-PTLD in the setting of lung transplantation.

查看原文本刊更多论文

在免疫缺陷和/或失调的情况下出现的淋巴瘤，也称为移植后淋巴组织增生性疾病（PTLD），通常与免疫抑制疗法和实体器官移植后的爱泼斯坦巴氏病毒有关。原发性中枢神经系统淋巴增生性疾病（PCNS-PTLD）极为罕见。我们的研究小组仅报告了第三例肺移植中的 PCNS-PTLD 病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation Reports Medicine-Transplantation

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

101 days

期刊介绍： To provide to national and regional audiences experiences unique to them or confirming of broader concepts originating in large controlled trials. All aspects of organ, tissue and cell transplantation clinically and experimentally. Transplantation Reports will provide in-depth representation of emerging preclinical, impactful and clinical experiences. -Original basic or clinical science articles that represent initial limited experiences as preliminary reports. -Clinical trials of therapies previously well documented in large trials but now tested in limited, special, ethnic or clinically unique patient populations. -Case studies that confirm prior reports but have occurred in patients displaying unique clinical characteristics such as ethnicities or rarely associated co-morbidities. Transplantation Reports offers these benefits: -Fast and fair peer review -Rapid, article-based publication -Unrivalled visibility and exposure for your research -Immediate, free and permanent access to your paper on Science Direct -Immediately citable using the article DOI